Located in Zhangjiang Hi-Tech Park in Pudong, the base is dubbed the 'Zhangjiang Pharma Valley' and is one of the top biotech hubs in China: home to over 1,000 biotechnology and biopharmaceutical companies.
Clover has access to over 25,000 square meters in real estate to build a facility including new preclinical research laboratory facilities, manufacturing process development labs, and a GMP pilot manufacturing plant. Construction of the R&D facilities is expected to be completed in the Q2, 2022; while the entire R&D center is planned to be completed in the second half of of the year.
The site will support development and pilot manufacturing based on Clover’s Trimer-Tag platform - a product development platform for the creation of novel vaccines and biologic therapies - and beyond (The Trimer-Tag platform has been used to create the company’s COVID-19 vaccine SCB-2019).
Clover intends to recruit hundreds of new hires to supplement its existing R&D capabilities and accelerate the development of multiple new product candidates.
Joshua Liang, CEO, Clover Biopharmaceuticals said: “Establishing a new R&D Center in Shanghai will allow us to expand our R&D capabilities and accelerate our innovative pipeline. In the future, we plan to establish additional R&D centers around the world as we advance the discovery and development of new innovative product candidates.”
The groundbreaking ceremony was attended by representatives from the Shanghai Municipal Commission of Economic and Information Technology, the Shanghai Pudong New Area Government and the Shanghai Zhangjiang Science City Administration, among others.
